Clinical Trial

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-02; most recent amendment 2026-04-09.
Status change: Not Yet Recruiting → Recruiting 2025-10-10
Trial Details
NCT Number NCT07062016
Lead Sponsor Mayo Clinic
Conditions Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
Enrollment 100 participants
Start Date 2025-10-01
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13